- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00016328
CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
A Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme
연구 개요
상태
개입 / 치료
상세 설명
OBJECTIVES:
I. Determine the efficacy of CCI-779, in terms of the percentage of patients who are progression-free at 6 months, time to progression, and time to death, in patients with recurrent glioblastoma multiforme.
II. Determine the toxic effects of this drug in these patients. III. Correlate molecular alterations in the tumors of these patients with response to treatment with this drug.
OUTLINE: This is a multicenter study. Patients are stratified according to concurrent P450 anticonvulsant use (yes vs no).
Patients receive CCI-779 IV over 30 minutes once weekly for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 6 months for 5 years and then annually for up to 10 years.
PROJECTED ACCRUAL: A total of 63 patients will be accrued for this study within 39 months.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- North Central Cancer Treatment Group
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Histologically confirmed grade 4 astrocytoma at primary diagnosis or recurrence
- Gliosarcoma allowed
- Evidence of tumor progression by MRI or CT scan after radiotherapy or first-line chemotherapy
- Measurable or evaluable disease by MRI or CT scan
- Performance status - ECOG 0-2
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 9 g/dL
- Bilirubin no greater than 1.5 mg/dL
- SGOT no greater than 3 times upper limit of normal
- Creatinine no greater than 2.0 mg/dL
- No myocardial infarction within the past 6 months
- No congestive heart failure requiring ongoing maintenance therapy for life-threatening ventricular arrhythmias
- Cholesterol no greater than 350 mg/dL
- Triglycerides no greater than 400 mg/dL
- Willing to provide correlative laboratory samples
- No uncontrolled infection
- No known hypersensitivity to any components of CCI-779, diphenhydramine hydrochloride, or other similar antihistamines
- No other medical reason that would preclude diphenhydramine premedication
- No other active malignancy
- No other severe disease that would preclude study participation
- Not immunocompromised unless due to corticosteroids
- HIV negative
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- See Disease Characteristics
- Prior adjuvant chemotherapy allowed
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)
- No more than 1 prior chemotherapy regimen for recurrent/progressive disease
- No prior polifeprosan 20 with carmustine implant (Gliadel)
- Must be on fixed dose of corticosteroids (or no corticosteroids) at least 1 week prior to baseline scan
- See Disease Characteristics
- At least 12 weeks since prior radiotherapy
- No prior stereotactic radiosurgery or interstitial brachytherapy unless there is a separate lesion on MRI that is outside of the previously treated field
- No prior resection since last chemotherapy or radiotherapy unless there is unequivocal tumor growth on neuro-imaging study since surgery or there is a separate lesion not present in the surgical bed
- More than 4 weeks since prior investigational agents
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Treatment (temsirolimus)
Patients receive CCI-779 IV over 30 minutes once weekly for 4 weeks.
Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
|
상관 연구
상관 연구
다른 이름들:
주어진 IV
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Percentage of patients being progression free
기간: 6 months
|
Ninety-five percent confidence intervals for the true proportion will be calculated according to the approach of Duffy and Santner.
|
6 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Percentage of patients that have not progressed
기간: 3 months
|
Ninety-five percent confidence intervals for the true proportion will be calculated according to the approach of Duffy and Santner.
|
3 months
|
Percentage of patients that have not progressed
기간: 12 months
|
Ninety-five percent confidence intervals for the true proportion will be calculated according to the approach of Duffy and Santner.
|
12 months
|
Percentage of patients that have not progressed
기간: 18 months
|
Ninety-five percent confidence intervals for the true proportion will be calculated according to the approach of Duffy and Santner.
|
18 months
|
Confirmed tumor response defined as an objective status of complete response (CR), partial response (PR), or regression (REGR) on two consecutive evaluations
기간: Up to 10 years
|
Ninety-five percent confidence intervals for the true proportion will be calculated using the exact binomial method.
|
Up to 10 years
|
Time to progression and death
기간: Up to 10 years
|
Estimated using Kaplan-Meier.
Frequency distributions of baseline patient characteristics will be compared using chi-squared and Wilcoxon tests.
|
Up to 10 years
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- NCI-2012-01858
- U10CA025224 (미국 NIH 보조금/계약)
- N997B
- CDR0000068623
- NCCTG-N997B
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
실험실 바이오마커 분석에 대한 임상 시험
-
ORIOL BESTARD완전한신장 이식 | CMV 감염스페인, 벨기에
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)아직 모집하지 않음
-
Hvidovre University HospitalElsassFonden종료됨
-
Spaarne GasthuisLeiden University Medical Center모집하지 않고 적극적으로
-
Rio de Janeiro State UniversityCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional de Desenvolvimento... 그리고 다른 협력자들완전한